FDA approves Glatopa 40 mg/mL generic option for relapsing MS

February 14, 2018
Sandoz announced the FDA approval and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa 40 mg/mL is a fully-substitutable, AP-rated generic version of Copaxone 40 mg/mL three times-a-week therapy for relapsing forms of multiple sclerosis.

Glatopa 40 mg/mL, along with Glatopa 20 mg/mL, will offer patients a complete range of dosing options. Glatopa 20 mg/mL was made available in the U.S. in June 2015. Patients can expect the same patient services for Glatopa 40 mg/mL as for Glatopa 20 mg/mL.

Sandoz GlatopaCare will offer a $0 co-pay support program to qualified patients. To help increase patient confidence with administering injections, patients will receive personalized injection training, 24-hour access to nurses for Glatopa-related questions and a free starter kit, which includes the Glatopaject injection device, designed to work with both Glatopa 20 mg/mL and 40 mg/mL prefilled syringes.

MS Focus Lending Library

Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Study uncovers potential risks of common MS treatment

Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more